Merck Extends Weizmann Institute Partnership

February 17, 2016 | Pharmaceutical giant Merck has extended its partnership with Israel’s Weizmann Institute of Science by signing a new framework agreement, building on a successful innovation partnership of almost four decades. “We have focused our healthcare research activities on the highly promising fields of immuno-oncology, immunology and oncology as we’re striving to deliver new solutions to respond to unmet medical needs,” Stefan Oschmann, Deputy CEO and Vice Chairman of the Executive Board of Merck said. “We’re excited that the new framework agreement will cover the first two of these three areas and are already looking forward to the proposals of the distinguished Weizmann scientists.” As part of the new framework agreement, the German pharma giant will fund each of the two research areas with up to €1 million per year over the three-year period initially.